Original and generic drugs: selection criteria, what a pharmacist needs to know

Announcement:

We invite you to watch an educational webinar featuring Svetlana Vadimovna Talashova,. The expert's presentation will explore the differences between original and generic medications, using Mexidol as an example.

• Why is the original drug not just a brand name, but the result of years of research and unique technology?
• How is the Mexidol molecule structured and why is its dual activity (antioxidant + antihypoxic) determined by its chemical structure?
• Why is succinate not just a filler, but a key element that influences cellular energy and microcirculation?
• Why does substitution with generic analogues risk losing the therapeutic effect, especially in neuroprotection?

The webinar provides a detailed examination of the pharmacokinetics of Mexidol:

• Dose-dependent effect;
• Fast elimination without accumulation;
• High safety profile.

Why aren't all "analogues" the same?

• Different salts (succinate vs. malate) = different pharmacological effects;
• Excipients: from stabilizers to adsorbents (for example, talc);
• Bioequivalence ≠ therapeutic equivalence.

Key point: Generic drugs are not subject to clinical trials. They are assessed only by bioequivalence (in 12 volunteers), not by efficacy in patients.

Only the original drug Mexidol:

• Included in Clinical Guidelines;
• It has a unique indication: ADHD in children from 6 years of age (proven in the MEGA study);
• It is used according to a well-founded scheme: 10–14 days of injections → 2 months of tablets (Mexidol Forte);
• It has a patented production technology and formula.

Watch the webinar to:

• Learn to competently explain to patients the difference between the original and the generic;
• Understand why Mexidol is an evidence-based choice;
• Learn how to use the State Register of Medicines to check the manufacturer and composition.

This webinar is a must-see for pharmacists, dispensing technicians, clinical pharmacologists, and physicians.